The EMJ Podcast | Episode 166
In the second part of this podcast, Jonathan and Mark de Boer, current president of the Dutch Working Party on Antibiotic Policy (SWAB) focus on the ‘marathon’ of antimicrobial resistance and common misconceptions surrounding this topic . De Boer then outlines the future of infectious disease management, highlighting the crucial role of healthcare professionals, policy makers, and the general public in combatting the ‘slow pandemic’.
Mark de Boer is Professor of Infectious Diseases at Leiden University Medical Center (LUMC) in the Netherlands, and the current president of the Dutch Working Party on Antibiotic Policy (SWAB).
After receiving his MD in 2001, Mark was trained as a resident in internal medicine at Bronovo Hospital in The Hague, the Netherlands, and LUMC, also in the Netherlands. Subsequently, he enrolled in the infectious disease fellow training programme in Leiden. After registering as an infectious disease specialist, he completed a PhD. His research focus shifted towards the increasing threat of antimicrobial resistance. As senior researcher, he has performed many studies on the understanding and improvement of antimicrobial treatment and stewardship.
In 2017, he was appointed to develop and chair a new national education programme in infectious diseases obligated for residents in internal medicine. Since February 2020, Mark has chaired the Dutch national advice on the medical therapy of COVID-19 for hospitalised patients. Next to his medical specialty, Mark is a qualified clinical epidemiologist. In 2019, he was elected a Fellow of the Infectious Disease Society of America (IDSA). He is a frequently invited lecturer, and has authored over 100 publications in the field of infectious diseases.
- Trends in antibiotic selection pressure generated in primary care and their association with sentinel antimicrobial resistance patterns in Europe
- The Dutch Working Party on Antibiotic Policy (SWAB) guideline for the approach to suspected antibiotic allergy